Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02852239
Other study ID # CDRB436A2106
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 19, 2016
Est. completion date September 27, 2019

Study information

Verified date July 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.


Description:

The main objective of this trial is to evaluate the pharmacokinetics of dabrafenib and metabolites after a single oral dose of dabrafenib in subjects with renal impairment as compared to healthy subjects with normal renal function. This was a single-dose, open-label, parallel group single dose study to evaluate the pharmacokinetics (PK) and safety of a single oral dose of dabrafenib 100 mg in subjects with severe RI or ESRD compared to matched healthy subjects with normal renal function (control group). The study consisted of a screening period, a treatment period and a follow-up period. The Screening period started up to 28 days prior to dosing. Subjects who satisfied the inclusion/exclusion criteria at screening were admitted for baseline evaluations, which was done locally by the investigator. In the treatment period, subjects received a single 100 mg oral dose of dabrafenib administered as two 50 mg capsules with a whole glass of non-carbonated water (approximately 240 mL) in the morning of Day 1 following an overnight fast (minimum 10 hours). Subjects were confined to the study facility from Day -1 to Day 5, for collection of serial blood and urine samples. Subjects were discharged on Day 5. In the follow-up period a telephone call was made to subjects 30 days post-dose to evaluate subject safety during the weeks after discharge from the facility. Adverse events occurring prior to Day 30 were followed until resolution or until judged to be permanent. Subjects returned to the clinic on Days 90 and 180 for the post-dose dermatological examination follow up. For this study, the terms "investigational drug", "study drug" or "study treatment" refer to dabrafenib, administered as a single dose.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date September 27, 2019
Est. primary completion date September 27, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: All subjects: - Females must be of non-childbearing potential or must have negative pregnancy results at screening - Good health as determined by lack of clinically significant findings - Subjects must have a BMI between 18.0 kg/m2 and 38.0 kg/m2, with a body weight of at least 50 kg and no more than 140 kg - Vitals signs within normal range - Laboratory values at screening within local normal ranges or considered non-clinically significant Additional criteria for renal impairment subjects: -Stable renal disease without evidence of renal progression in the past 28 days prior to dosing Additional criteria for healthy matched subjects: - Matched to at least 1 renal impairment subject by race, age (+/-10 years), gender and weight (+/-10%) - An absolute GFR of at least 90 ml/min Exclusion Criteria for all subjects: - Significant acute illness within the two weeks prior to dosing - History or current diagnosis of cardiac disease indicating significant risk such as uncontrolled or significant cardiac disease or clinically significant ECG abnormalities - Subjects will be screened for drugs of abuse - History of drug or alcohol abuse within 6 months prior to dosing or evidence of such abuse as indicated by laboratory values at screening or baseline. - Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs. - History of malignancy of any organ system, treated or untreated, within 5 years, regardless of where there is recurrence or metastases. - Use of drugs known to prolong the QT interval within 4 weeks prior to dosing and for the duration of the study. - Use of drugs know to affect CYP3A4 and/or CYP2C8 including both (strong or moderate) inhibitors and inducers, within 7 days prior to dosing or during the current study are prohibited

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dabrafenib
Single dose dabrafenib 100 mg

Locations

Country Name City State
United States Hassman Research Institute Berlin New Jersey
United States Omega Research Consultants LLC DeBary Florida
United States Wake Research Associates Oncology Raleigh North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum plasma concentration (Cmax) The maximum (peak) observed plasma drug concentration after a single dose of dabrafenib Predose through 96 hours postdose
Primary Area under the curve (AUClast) AUClast is the area under the curve calculated to the last quantifiable concentration point after a single dose of dabrafenib Predose through 96 hours postdose
Primary Area under the curve (AUFinf) AUCinf is the area under the plasma concentration time curve extrapolated to infinity after a single dose of dabrafenib Predose through 96 hours postdose
Primary Systemic drug clearance (CL/F) Systemic clearance from plasma of dabrafenib after a single dose Predose through 96 hours postdose
Primary Time to reach maximum concentration (Tmax) The time to reach maximum (peak) concentration of dabrafenib after a single dose Predose through 96 hours postdose
Primary Terminal elimination rate (Lambda_z) Terminal elimination rate of dabrafenib after a single dose Predose through 96 hours postdose
Primary Elimination half-life (T1/2) Elimination half-life of dabrafenib after a single dose Predose through 96 hours postdose
Primary Volume of distribution (Vz/F) The apparent volume of distribution during the terminal elimination phase of dabrafenib after a single dose Predose through 96 hours postdose
Primary Unchanged drug excreted in urine (Aet) The amount of unchanged dabrafenib excreted in urine after a single dose Predose through 96 hours postdose
Primary Renal clearance (CLr) Renal clearance of dabrafenib calculated using plasma AUC after a single dose Predose through 96 hours postdose
Secondary Number of subjects with adverse events Assess the safety of a single dose of dabrafenib through AE reports of subjects from drug administration through 30 days postdose Time of drug administration through 30 days postdose
Secondary Number of subjects with abnormal lab values related to study drug Assess the safety of a single dose of dabrafenib through hematology and chemistry blood tests Time of study drug administration through 30 days postdose
Secondary Number of subjects with abnormal blood pressure related to study drug Assess the safety of a single dose of dabrafenib by monitoring changes in blood pressure Time of study drug administration through 30 days postdose
Secondary Changes in electrocardiogram (ECG) Assess the safety of a single dose of dabrafenib by monitoring changes in ECG Time of study drug administration through 30 days postdose
Secondary Number of subjects with abnormal pulse rate related to study drug Assess the safety of a single dose of dabrafenib by monitoring changes in heart rate Time of study drug administration through 30 days postdose
Secondary Number of subjects with abnormal respiratory rate related to study drug Assess the safety of a single dose of dabrafenib by monitoring changes in respiratory rate Time of study drug administration through 30 days postdose
See also
  Status Clinical Trial Phase
Completed NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Phase 1
Completed NCT03284164 - Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex Phase 1
Completed NCT05992155 - A Study of TAK-279 in Adults With or Without Kidney Problems Phase 1
Completed NCT05004311 - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Phase 1
Completed NCT04963738 - A Study of JNJ-73763989 in Adult Participants With Renal Impairment Phase 1
Terminated NCT02508740 - Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Phase 1
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Terminated NCT00984113 - Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00750620 - A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00499187 - Fanconi Syndrome Due to ARVs in HIV-Infected Persons Phase 4
Completed NCT01331941 - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Phase 1
Completed NCT05489614 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment Phase 1
Completed NCT03259087 - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) Phase 1
Completed NCT05086107 - Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment Phase 1
Recruiting NCT05349851 - Bowel Cleansing With Renal Impairment
Completed NCT03660241 - A Renal Impairment Study for PF-04965842 Phase 1
Recruiting NCT06037031 - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function Phase 1
Completed NCT03289208 - Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment Phase 1
Completed NCT02942810 - To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment Phase 1